Teza Capital Management LLC Corcept Therapeutics Inc Transaction History

Teza Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$21.1 - $27.46 $139,766 - $181,895	6,624 Added 102.92%	13,060 $328,000
Q4 2023 Feb 14, 2024	SELL	$24.82 - $32.88 $228,219 - $302,331	-9,195 Reduced 58.83%	6,436 $209,000
Q3 2023 Feb 22, 2024	BUY	$21.97 - $33.8 $24,848 - $38,227	1,131 Added 17.57%	7,567 $206,000
Q3 2023 Nov 14, 2023	BUY	$21.97 - $33.8 $113,387 - $174,441	5,161 Added 49.29%	15,631 $425,000
Q2 2023 Aug 14, 2023	BUY	$21.44 - $25.15 $224,476 - $263,320	10,470 New	10,470 $232,000
Q3 2020 Nov 12, 2020	SELL	$12.46 - $19.98 $447,550 - $717,661	-35,919 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$11.0 - $18.26 $395,109 - $655,880	35,919 New	35,919 $604,000
Q1 2020 May 11, 2020	SELL	$10.11 - $14.04 $375,515 - $521,487	-37,143 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$12.06 - $16.96 $447,944 - $629,945	37,143 New	37,143 $449,000

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.16B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Teza Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Teza Capital Management LLC with notifications on news.